Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluticasone Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 14/20 | 0.95 |
| ▸ | PGR | P06401 | 5/20 | 0.95 |
| ▸ | AR | P10275 | 5/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.95 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.95 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.95 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluticasone Propionate SCHEMBL4622987 | 0.98 | NR3C1 (0.94) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL15325049 | 0.98 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL4283 | 0.98 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL191134 | 0.98 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL4111260 | 0.98 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL5482829 | 0.98 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL13993454 | 0.98 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL14339613 | 0.98 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL191133 | 0.98 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL14343427 | 0.98 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390363-B2 | Ophthalmic drug compositions | OXULAR LIMITED (GB) | 2025-08-19 | — | — | US | claimed |
| CN-118465142-B | Method for measuring content of microscale span 20 in inhalation suspension | 四川健林药业有限责任公司 | 2024-09-10 | — | — | CN | claimed |
| CN-118465142-A | Method for measuring content of microscale span 20 in inhalation suspension | 四川健林药业有限责任公司 | 2024-08-09 | — | — | CN | claimed |
| CN-111712228-B | Ophthalmic pharmaceutical composition | 奥叙拉尔有限公司 | 2024-05-07 | — | — | CN | claimed |
| US-20230355431-A1 | Ophthalmic Drug Compositions | OXULAR LIMITED (GB) | 2023-11-09 | — | — | US | claimed |
| US-11564834-B2 | Sterile lyophilized drug compositions and methods for treating ocular diseases or conditions | OXULAR LIMITED (GB) | 2023-01-31 | — | — | US | claimed |
| CN-111712229-A | Ophthalmic delivery device | 奥叙拉尔有限公司 | 2020-09-25 | — | — | CN | claimed |
| CN-111712228-A | Ophthalmic pharmaceutical composition | 奥叙拉尔有限公司 | 2020-09-25 | — | — | CN | claimed |
| US-20200276111-A1 | Ophthalmic Drug Compositions | OXULAR LIMITED (GB) | 2020-09-03 | — | — | US | claimed |
| US-20200261266-A1 | Ophthalmic Delivery Device | OXULAR LIMITED (GB) | 2020-08-20 | — | — | US | claimed |
| US-20070256685-A1 | Aerosol Formulations Comprising Formoterol Fumarate Dihydrate | JAGOTECH AG (CH) | 2007-11-08 | — | — | US | claimed |
| US-20070218011-A1 | Aerosol Formulation Comprising Formoterol in Suspension | JAGOTEC AG (CH) | 2007-09-20 | — | — | US | claimed |
| EP-1670443-A2 | AEROSOL FORMULATION COMPRISING FORMOTEROL IN SUSPENSION | JAGOTEC AG (CH) | 2006-06-21 | — | — | EP | claimed |
| EP-1670432-A1 | AEROSOL FORMULATIONS COMPRISING FORMOTEROL FUMARATE DIHYDRATE, A PROPELLANT, ETHANOL AND OPTIONALLY A STEROID, WHERE THE FORMOTEROL FUMARATE DIHYDRATE HAS A WATER CONTENT OF 4.8-4.28% BY WEIGHT. | JAGOTEC AG (CH) | 2006-06-21 | — | — | EP | claimed |
| WO-2005055985-A1 | METERED DOSE INHALATION PREPARATIONS OF THERAPEUTIC DRUGS | MEDPHARM LIMITED (GB) | 2005-06-23 | — | — | WO | claimed |
| WO-2005034911-A1 | AEROSOL FORMULATIONS COMPRISING FORMOTEROL FUMARATE DIHYDRATE, A PROPELLANT,ETHANOL AND OPTIONALLY A STEROID,WHERE THE FORMOTEROL FUMARATE DIHYDRATE HAS A WATER CONTENT OF 4.8-4.28% BY WEIGHT | JAGOTEC AG (CH) | 2005-04-21 | — | — | WO | claimed |
| WO-2005034927-A2 | AEROSOL FORMULATION COMPRISING FORMOTEROL IN SUSPENSION | JAGOTEC AG (CH) | 2005-04-21 | — | — | WO | claimed |
| US-20030091513-A1 | Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media | SHEFFIELD PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | claimed |
| EP-0627910-B1 | METHODS AND APPARATUS FOR DRUG DELIVERY USING SUPERCRITICAL SOLUTIONS | SIEVERS ROBERT E (US) | 1997-10-01 | — | — | EP | claimed |
| US-5301664-A | Methods and apparatus for drug delivery using supercritical solutions | SIEVERS ROBERT E (US) | 1994-04-12 | — | — | US | claimed |